# BioNTech SE: Phase 1 study closed enrollment, 318 enrolled (Genital Herpes Simplex Type 2)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | BioNTech SE |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions |
| NCT ID | NCT05432583 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Genital Herpes Simplex Type 2 |
| Intervention types | biological, other |
| Target enrollment | 318 |
| Site countries | United States |
| Posted | 2022-06-27 |
| Planned start | 2022-12-08 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-22 |
| Last update posted | 2026-10-22 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 318 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05432583). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.